COVID-19 outcomes in paediatric cancer: A large scale pooled meta-analysis of 984 cancer patients.

We aimed to study the outcomes of COVID-19 in paediatric cancer patients. On 26 October 2021, we did a systematic search for relevant articles in seven electronic databases followed by manual search. We included cancer patients aged ≤18 years. Event rates and the 95% confidence interval (95%CI) were used to report the results. We included 21 papers after screening of 2759 records. The pooled rates of hospitalisation, intensive care unit (ICU) admission and mortality were 44% (95%CI: 30-59), 14% (95%CI: 9-21) and 9% (95%CI: 6-12), respectively. Moreover, subgroup analysis revealed that high income countries had better COVID-19 outcomes compared to upper middle income countries and lower middle income countries in terms of hospitalisation 30% (95%CI: 17-46), 60% (95%CI: 29-84) and 47% (95%CI: 36-58), ICU admission 7% (95%CI: 1-32), 13% (95%CI: 7-23) and 18% (95%CI: 6-41), and mortality 3% (95%CI: 2-5), 12% (95%CI: 8-18) and 13% (95%CI: 8-20), in order. In general, absence of specific pharmacologic intervention to prevent infection with the scarcity of vaccination coverage data among paediatric groups and its impact, high priority caution is required to avoid SARS-CoV-2 infection among paediatric cancer patients. Furthermore, our results highlight the importance of promoting care facilities for this vulnerable population in low and middle income regions to ensure quality care among cancer patients during pandemic crisis.